[1]崔 伟,王光翌.乳腺癌患者血清FGF9、CDCP1、FOXA2水平变化及检测意义[J].陕西医学杂志,2026,(5):653-658,663.[doi:DOI:10.3969/j.issn.1000-7377.2026.05.014]
　CUI Wei,WANG Guangyi.Changes and detection significance of serum FGF9,CDCP1 and FOXA2 levels in breast cancer patients[J].,2026,(5):653-658,663.[doi:DOI:10.3969/j.issn.1000-7377.2026.05.014]
点击复制

乳腺癌患者血清FGF9、CDCP1、FOXA2水平变化及检测意义

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2026年5期
页码:
653-658,663
栏目:
临床研究
出版日期:
2026-05-05

文章信息/Info

Title:
Changes and detection significance of serum FGF9,CDCP1 and FOXA2 levels in breast cancer patients
作者:
崔 伟1; 王光翌2
（1.保定市第二医院肿瘤外科，河北 保定 071000；2.保定市第二医院神经外科，河北 保定 071000）
Author(s):
CUI Wei1; WANG Guangyi2
（1.Department of Surgical Oncology,Baoding Second Hospital,Baoding 071000,China;2.Department of Neurosurgery,Baoding Second Hospital,Baoding 071000,China）
关键词:
乳腺癌; 成纤维细胞生长因子9; 含CUB结构域的蛋白质1; 叉头框蛋白A2; 预后; 影响因素
Keywords:
Breast cancer; Fibroblast growth factor 9; CUB domain containing protein 1; Forkhead box protein A2; Prognosis; Influencing factors
分类号:
R737.9
DOI:
DOI:10.3969/j.issn.1000-7377.2026.05.014
文献标志码:
A
摘要:
目的：探讨乳腺癌患者血清成纤维细胞生长因子9（FGF9）、含CUB结构域的蛋白质1（CDCP1）、叉头框蛋白A2（FOXA2）水平变化及检测意义。方法：选取129例乳腺癌患者为疾病组，根据随访3年结果将患者分为预后不良组（51例）和预后良好组（78例）。另选取同期体检健康女性87名为对照组。ELISA法检测血清FGF9、CDCP1、FOXA2水平；多因素Logistic回归分析影响患者预后的因素；受试者工作特征（ROC）曲线分析血清FGF9、CDCP1、FOXA2对患者预后的预测价值。结果：疾病组血清FGF9、CDCP1水平较对照组升高，血清FOXA2水平较对照组降低（均P＜0.05）。不同TNM分期、肿瘤直径、淋巴结转移情况的乳腺癌患者血清FGF9、CDCP1、FOXA2水平之间比较差异有统计学意义（均P＜0.05）。预后不良组和预后良好组TNM分期、肿瘤直径、淋巴结转移情况及血清FGF9、CDCP1、FOXA2水平比较差异有统计学意义（均P＜0.05）。TNM分期、肿瘤直径、淋巴结转移以及血清FGF9、CDCP1、FOXA2是患者预后的影响因素（均P＜0.05）。血清FGF9、CDCP1、FOXA2三者联合预测的曲线下面积（AUC）高于各自单独预测的AUC（均P＜0.05）。结论：乳腺癌患者血清FGF9、CDCP1水平升高，FOXA2水平降低，且与预后有关，三者联合检测对患者预后评估具有一定的参考价值。
Abstract:
Objective:To investigate the changes in serum levels of fibroblast growth factor 9 (FGF9),CUB domain containing protein 1 (CDCP1) and forkhead box protein A2 (FOXA2) in breast cancer patients and their detection significance.Methods：A total of 129 breast cancer patients were enrolled as the disease group.According to the 3-year follow-up results,patients were divided into the poor prognosis group (51 cases) and the good prognosis group (78 cases).Additionally,87 healthy women were selected as the control group.Serum levels of FGF9,CDCP1 and FOXA2 were measured by ELISA.Multivariate logistic regression analysis was performed to identify factors affecting patient prognosis.ROC curve analysis was used to evaluate the predictive value of serum FGF9,CDCP1 and FOXA2 for patient prognosis.Results:Serum levels of FGF9 and CDCP1 in the disease group were higher than those in the control group,while serum FOXA2 level was lower than that in the control group (all P<0.05).There were statistically significant differences in serum FGF9,CDCP1 and FOXA2 levels among breast cancer patients with different TNM stages,tumor diameters,and lymph node metastasis statuses (all P<0.05).Significant differences were observed between the poor prognosis group and the good prognosis group in TNM stage,tumor diameter,lymph node metastasis status,and serum levels of FGF9,CDCP1 and FOXA2 (all P<0.05).TNM stage,tumor diameter,lymph node metastasis,and serum FGF9,CDCP1 and FOXA2 were influencing factors for patient prognosis (all P<0.05).The AUC of the combined prediction using serum FGF9,CDCP1 and FOXA2 was higher than that of each individual predictor (all P<0.05).Conclusion:Serum FGF9 and CDCP1 levels are elevated,while FOXA2 level is decreased in breast cancer patients,and these are associated with prognosis.Combined detection of these three markers has certain reference value for prognostic evaluation in breast cancer patients.

参考文献/References:

[1]SUNG H,FERLAY J,SIEGEL R L,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[2]BARZAMAN K,KARAMI J,ZAREI Z,et al.Breast cancer:Biology,biomarkers,and treatments[J].Int Immunopharmacol,2020,84(1):106535.
[3]王玉龙,张美荣,周昱.乳腺癌患者血清微小RNA-135b、微小RNA-148a-3p、微小RNA-186-5p表达水平及其与新辅助化疗效果相关性研究[J].陕西医学杂志,2024,53(5):684-687,691.
[4]CHANG M M,WU S Z,YANG S H,et al.FGF9/FGFR1 promotes cell proliferation,epithelial-mesenchymal transition,M2 macrophage infiltration and liver metastasis of lung cancer[J].Transl Oncol,2021,14(11):101208.
[5]XU J,SUN P,ZHU W,et al.FGF19 in solid tumors:Molecular mechanisms,metabolic reprogramming,and emerging therapeutic opportunities[J].Theranostics,2026,16(1):345-397.
[6]QI X,GAO J,LI Z,et al.CDCP1:A promising diagnostic biomarker and therapeutic target for human cancer[J].Life Sci,2022,301(1):120600.
[7]JIN S,HE J,ZHOU Y,et al.LncRNA FTX activates FOXA2 expression to inhibit non-small-cell lung cancer proliferation and metastasis[J].J Cell Mol Med,2020,24(8):4839-4849.
[8]MA G,CHEN J,WEI T,et al.Inhibiting roles of FOXA2 in liver cancer cell migration and invasion by transcriptionally suppressing microRNA-103a-3p and activating the GREM2/LATS2/YAP axis[J].Cytotechnology,2021,73(4):523-537.
[9]马英桥,李建梅,孙静宜.外周血循环肿瘤细胞及血清催乳素、游离前列腺抗原与乳腺癌患者术后转移相关性研究[J].陕西医学杂志,2023,52(7):855-857,884.
[10]中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J].中国癌症杂志,2021,31(10):954-1040.
[11]徐慧慧,霍英杰,王红辉,等.DCE-MRI联合血清TM4SF1、HER-2对乳腺癌的诊断价值[J].检验医学与临床,2024,21(24):3714-3718.
[12]LI Y,ZHANG H,MERKHER Y,et al.Recent advances in therapeutic strategies for triple-negative breast cancer[J].J Hematol Oncol,2022,15(1):121.
[13]徐梦姗,刘侠,岳亚丽,等.黄芪桃红汤联合姑息化疗治疗乳腺癌疗效观察[J].陕西中医,2024,45(11):1508-1511.
[14]王瑾琳,张颖杰,郭锐.血清CCL20、β2-MG与乳腺癌患者术后复发转移及预后的关系[J].实用癌症杂志,2024,39(4):667-670.
[15]CRUCERIU D,BALDASICI O,BALACESCU O,et al.The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer:Molecular insights and therapeutic approaches[J].Cell Oncol (Dordr),2020,43(1):1-18.
[16]CHANG M M,WENG H Y,LAI M S,et al.FGF9 promotes cell proliferation and tumorigenesis in TM3 mouse Leydig progenitor cells[J].Am J Cancer Res,2022,12(12):5613-5630.
[17]冯博琳,常静,柳馨.血清sCD164、FGF9水平对晚期非小细胞肺癌患者化疗疗效及预后的评估价值[J].国际检验医学杂志,2024,45(24):2977-2982.
[18]ZHANG B,LIU Y,YU J,et al.Upregulation of FGF9 and NOVA1 in cancer-associated fibroblasts promotes cell proliferation,invasion and migration of triple negative breast cancer[J].Drug Dev Res,2024,85(3):e22185.
[19]KHAN T,KRYZA T,LYONS N J,et al.The CDCP1 signaling hub:A target for cancer detection and therapeutic intervention[J].Cancer Res,2021,81(9):2259-2269.
[20]LIM S A,ZHOU J,MARTINKO A J,et al.Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers[J].J Clin Invest,2022,132(4):154604.
[21]熊云刚,成克伦,赵露,等.NSCLC患者血清中PTBP1、CDCP1的表达及临床预后意义[J].国际检验医学杂志,2023,44(12):1507-1511，1521.
[22]ZHAO J,MEI J,WANG F,et al.Overexpression of CDCP1 is associated with poor prognosis and enhanced immune checkpoints expressions in breast cancer[J].J Oncol,2022,2022:1469354.
[23]HONG L,CHEN M,HUANG M,et al.FOXA2 suppresses gallbladder carcinoma cell migration,invasion,and epithelial-mesenchymal transition by targeting SERPINB5[J].Environ Toxicol,2024,39(2):708-722.
[24]LIU X,YAN C,CHANG C,et al.FOXA2 suppression by TRIM36 exerts anti-tumor role in colorectal cancer via inducing NRF2/GPX4-regulated ferroptosis[J].Adv Sci (Weinh),2023,10(35):2304521.
[25]LIU Y,CHEN T,GUO M,et al.FOXA2-interacting FOXP2 prevents epithelial-mesenchymal transition of breast cancer cells by stimulating E-cadherin and PHF2 transcription[J].Front Oncol,2021,11(1):605025.

相似文献/References:

[1]乔亚舜,吴瑛琦.乳腔镜腋窝淋巴结清扫术治疗早期乳腺癌临床研究[J].陕西医学杂志,2019,(4):473.
　QIAO Yashun,WU Yingqi..Clinical study of mammoscopic axillary lymph node dissection for early breast cancer patients[J].,2019,(5):473.
[2]谭兴利,陆伟辉,汤学文,等.乳腺癌患者超声检查中PSV、RI值与术后组织中MMP11、VEGF表达的相关性探讨[J].陕西医学杂志,2019,(5):617.
[3]韩丕华,宋张骏△,杨晓民,等.乳腺超声造影联合细针穿刺定位活检在判定乳腺癌新辅助化疗后腋窝淋巴结性质中的临床研究*[J].陕西医学杂志,2019,(7):842.
　HAN Pihua,SONG Zhangjun,YANG Xiaomin,et al.Application of breast contrast-enhanced ultrasonography combined with fine needle aspiration biopsy in determining the axillary lymph node properties after neoadjuvant chemotherapy for breast cancer[J].,2019,(5):842.
[4]蒋 敢,王 军,王会东△.舒芬太尼联合罗哌卡因肋间神经阻滞对乳腺癌患者术后镇痛、免疫功能及应激反应的影响*[J].陕西医学杂志,2019,(8):1077.
　JIANG Gan,WANG Jun,WANG Huidong..Effect of sufentanil plus ropivacaine intercostal nerve block on postoperative analgesia, immunity and stress response in patients with breast cancer[J].,2019,(5):1077.
[5]王群拴,黎小花△.核磁共振结合血清肿瘤标志物及细胞因子检测在〖JZ〗乳腺癌诊断中的应用价值研究*[J].陕西医学杂志,2019,(10):1295.
[6]韩丕华,袁 权△.乳腺癌患者白细胞介素-22表达水平对新辅助化疗后病理学完全缓解的预测价值*[J].陕西医学杂志,2020,49(7):889.[doi:DOI:10.3969/j.issn.10007377.2020.07.033]
　HAN Pihua,YUAN Quan..Predictive value of IL-22 expression level in breast cancer patients for pathological complete remission after neoadjuvant chemotherapy[J].,2020,49(5):889.[doi:DOI:10.3969/j.issn.10007377.2020.07.033]
[7]韩金怡,苏志勇.21基因检测对早期Luminal A型乳腺癌治疗指导作用研究[J].陕西医学杂志,2021,50(9):1081.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.010]
　HAN Jinyi,SU Zhiyong.Guiding role of 21-gene detection in treatment of early Luminal type A breast cancer[J].,2021,50(5):1081.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.010]
[8]白玲娇,陈小军,王 婷.乳腺癌超声弹性成像评分与免疫组化指标表达水平相关性分析[J].陕西医学杂志,2021,50(10):1239.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.015]
[9]郑 超,苏 娟,盛杰鑫,等.乳腺癌患者病灶血流时间-信号强度曲线类型、表观弥散系数与化疗疗效相关性分析[J].陕西医学杂志,2021,50(12):1521.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.013]
　ZHENG Chao,SU Juan,SHENG Jiexin,et al.Correlation between focal blood flow time-signal intensity curve type,apparent diffusion coefficient and chemotherapy efficacy in breast cancer patients[J].,2021,50(5):1521.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.013]
[10]李福平,王 茂,邱春丽,等.莱菔硫烷联合维生素D对乳腺癌细胞增殖及凋亡的影响[J].陕西医学杂志,2022,51(8):916.[doi:DOI:10.3969/j.issn.1000-7377.2022.08.003]
　LI Fuping,WANG Mao,QIU Chunli,et al.Effect of sulforaphane combined with vitamin D on proliferation and apoptosis of breast cancer cells[J].,2022,51(5):916.[doi:DOI:10.3969/j.issn.1000-7377.2022.08.003]

备注/Memo

备注/Memo:
河北省医学科学研究课题（20210401）
更新日期/Last Update: 2026-05-05